BeiGene
BGNE
#908
Rank
S$29.40 B
Marketcap
$261.10
Share price
3.46%
Change (1 day)
3.90%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

Market capitalization of BeiGene (BGNE)

Market cap: S$29.40 Billion

As of November 2024 BeiGene has a market cap of S$29.40 Billion. This makes BeiGene the world's 908th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.

Market cap history of BeiGene from 2016 to 2024

End of year Market Cap

Year Marketcap Change
2024S$29.40 B12.36%
2023S$26.17 B-16.78%
2022S$31.45 B-15.37%
2021S$37.16 B16.9%
2020S$31.79 B129.2%
2019S$13.87 B21.82%
2018S$11.38 B91.29%
2017S$5.95 B241.41%
2016S$1.74 B

End of Day market cap according to different sources

On Nov 20th, 2024 the market cap of BeiGene was reported to be:

S$29.14 Billion
by Yahoo Finance info icon info icon
S$29.14 Billion
by CompaniesMarketCap info icon info icon
S$27.83 Billion
by Nasdaq info icon info icon

Market capitalization for similar companies or competitors

Name Marketcap Market cap differencediff. Country
S$28.09 M-99.90%๐Ÿ‡บ๐Ÿ‡ธ USA
S$1.42 B-95.14%๐Ÿ‡บ๐Ÿ‡ธ USA